KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally

KEYTRUDA ® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally#KEYTRUDA #pembrolizumab #Perioperative #Treatment #Standard #Care #SOC #Adjuvant #Therapy #Significantly #Improved #EventFree #Survival #Compared #SOC #Patients #Resectable #Locally